Jack Anders - 16 Jun 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RVMD
Reported as of: 16 Jun 2025
Net transaction value: -$86,431
SEC form: 4
Accepted by SEC: 18 Jun 2025, 16:05:51 UTC
Prior SEC filing: 19 Mar 2025
Next SEC filing: 04 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Jun 2025.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2025, 16:05.

Change

Previous filing in this sequence was filed on 19 Mar 2025.
Current net transaction value: -$86,431.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001800668 Primary reporting owner

Anders Jack

Relationship: Chief Financial Officer
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders
Signature date: 18 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $86,431
Shares: -2,170
Change %: -1.9%
Price: $39.83
Shares after: 113,314
Date: 16 Jun 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

Footnote F2

This transaction was executed in multiple trades in prices ranging from $39.5913 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 478 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Footnote F4

Includes 54,213 RSUs.